FI952328A0 - eck-respetorin lignandeja - Google Patents

eck-respetorin lignandeja

Info

Publication number
FI952328A0
FI952328A0 FI952328A FI952328A FI952328A0 FI 952328 A0 FI952328 A0 FI 952328A0 FI 952328 A FI952328 A FI 952328A FI 952328 A FI952328 A FI 952328A FI 952328 A0 FI952328 A0 FI 952328A0
Authority
FI
Finland
Prior art keywords
ligands
eck
disclosed
eck receptor
receptor
Prior art date
Application number
FI952328A
Other languages
English (en)
Swedish (sv)
Other versions
FI952328A (fi
Inventor
Timothy D Bartley
William J Boyle
Gary M Fox
Andrew A Welcher
Vann P Parker
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of FI952328A0 publication Critical patent/FI952328A0/fi
Publication of FI952328A publication Critical patent/FI952328A/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
FI952328A 1992-11-13 1995-05-12 eck-respetorin lignandeja FI952328A (fi)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US97770892A 1992-11-13 1992-11-13
US14561693A 1993-11-09 1993-11-09
PCT/US1993/010879 WO1994011020A1 (en) 1992-11-13 1993-11-12 Eck receptor ligands

Publications (2)

Publication Number Publication Date
FI952328A0 true FI952328A0 (fi) 1995-05-12
FI952328A FI952328A (fi) 1995-07-10

Family

ID=26843152

Family Applications (1)

Application Number Title Priority Date Filing Date
FI952328A FI952328A (fi) 1992-11-13 1995-05-12 eck-respetorin lignandeja

Country Status (14)

Country Link
US (2) US5650504A (fi)
EP (1) EP0597503B1 (fi)
JP (1) JPH08505765A (fi)
CN (1) CN1094446A (fi)
AT (1) ATE172246T1 (fi)
AU (1) AU685765B2 (fi)
CA (1) CA2149333C (fi)
DE (1) DE69321555T2 (fi)
DK (1) DK0597503T3 (fi)
ES (1) ES2121915T3 (fi)
FI (1) FI952328A (fi)
IL (1) IL107599A0 (fi)
NO (1) NO951861L (fi)
WO (1) WO1994011020A1 (fi)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU8931291A (en) * 1990-10-16 1992-05-20 Regents Of The University Of Michigan, The Cytokine-induced marker for inflammatory response
US5824303A (en) * 1992-11-13 1998-10-20 Amgen Inc. Eck receptor ligands
PT669929E (pt) * 1992-11-13 2007-04-30 Immunex Corp Ligando de elk, uma citoquina
US5516658A (en) * 1993-08-20 1996-05-14 Immunex Corporation DNA encoding cytokines that bind the cell surface receptor hek
US5747033A (en) * 1993-10-28 1998-05-05 Regeneron Pharmaceuticals, Inc. Method of enhancing the biological activity of Eph family ligands
CA2187167A1 (en) * 1994-04-04 1995-10-12 Samuel Davis Biologically active eph family ligands
US6303769B1 (en) 1994-07-08 2001-10-16 Immunex Corporation Lerk-5 dna
DE69532857T2 (de) * 1994-10-27 2005-04-28 Genentech Inc., San Francisco Neurotrophischer AL-1 Faktor, einer Ligand verwandt mit dem EPH Tyrosine Kinase Receptor
US5759775A (en) 1994-10-27 1998-06-02 Genetech, Inc. Methods for detecting nucleic acids encoding AL--1 neurotrophic factor
US6057124A (en) * 1995-01-27 2000-05-02 Amgen Inc. Nucleic acids encoding ligands for HEK4 receptors
US6100346A (en) * 1995-03-06 2000-08-08 Ethicon, Inc. Copolymers of polyoxaamides
US6610296B2 (en) 1995-10-26 2003-08-26 Genentech, Inc. Methods of enhancing cognitive function using an AL-1 neurotrophic factor immunoadhesin
US6887674B1 (en) 1998-04-13 2005-05-03 California Institute Of Technology Artery- and vein-specific proteins and uses therefor
US6864227B1 (en) 1998-04-13 2005-03-08 California Institute Of Technology Artery-and vein-specific proteins and uses therefor
EP1141294B1 (en) 1998-12-23 2005-03-02 Regeneron Pharmaceuticals, Inc. Method of enhancing the biological activity of ligands
US6248725B1 (en) 1999-02-23 2001-06-19 Amgen, Inc. Combinations and methods for promoting in vivo liver cell proliferation and enhancing in vivo liver-directed gene transduction
EP1867719A3 (en) * 1999-06-02 2008-03-19 Genentech, Inc. Methods and compositions for inhibiting neoplastic cell growth
US7192698B1 (en) 1999-08-17 2007-03-20 Purdue Research Foundation EphA2 as a diagnostic target for metastatic cancer
US6927203B1 (en) 1999-08-17 2005-08-09 Purdue Research Foundation Treatment of metastatic disease
US7101976B1 (en) 2000-09-12 2006-09-05 Purdue Research Foundation EphA2 monoclonal antibodies and methods of making and using same
WO2002086460A1 (en) * 2001-04-20 2002-10-31 Consensus Pharmaceuticals, Inc. Methods for identifying ligands of g-protein-coupled receptors
US20050152899A1 (en) * 2002-05-10 2005-07-14 Kinch Michael S. EphA2 agonistic monoclonal antibodies and methods of use thereof
WO2003094859A2 (en) * 2002-05-10 2003-11-20 Medimmune, Inc. Epha2 monoclonal antibodies and methods of use thereof
JP4585968B2 (ja) * 2002-05-10 2010-11-24 パーデュー・リサーチ・ファウンデーション ＥｐｈＡ２アゴニストモノクローナル抗体およびその使用法
AU2003268345A1 (en) 2002-09-24 2004-04-19 The Burnham Institute Novel agents that modulate eph receptor activity
US7381410B2 (en) 2003-03-12 2008-06-03 Vasgene Therapeutics, Inc. Polypeptide compounds for inhibiting angiogenesis and tumor growth
AU2004220525B2 (en) 2003-03-12 2011-03-31 Vasgene Therapeutics, Inc. Nucleic acid compounds for inhibiting angiogenesis and tumor growth
EP1618184A4 (en) * 2003-04-11 2006-06-21 Medimmune Inc EPHA2, HYPOPROLIFERATIVE CELL DISORDERS, AND EPITHELIAL AND ENDOTHELIAL RECONSTITUTION
CA2521594A1 (en) * 2003-04-11 2004-10-28 Medimmune, Inc. Epha2 and non-neoplastic hyperproliferative cell disorders
EP1628992A4 (en) * 2003-05-13 2008-04-16 Novartis Vaccines & Diagnostic METHODS FOR MODULATING METASTASIS AND SKELETAL RELATED EVENTS RESULTING FROM METASTASES
WO2005090406A2 (en) 2004-03-12 2005-09-29 Vasgene Therapeutics, Inc. Antibodies binding to ephb4 for inhibiting angiogenesis and tumor growth
CN102718867A (zh) 2004-03-12 2012-10-10 瓦斯基因治疗公司 结合ephb4、抑制血管发生和肿瘤生长的抗体
EP2301963A1 (en) 2004-09-23 2011-03-30 Vasgene Therapeutics, Inc. Polypeptide compounds for inhibiting angiogenesis and tumor growth
EP1841790B1 (en) 2005-01-27 2010-11-03 The Burnham Institute Ephb receptor-binding peptides
AU2008287427B2 (en) 2007-08-13 2014-10-09 Vasgene Therapeutics, Inc. Cancer treatment using humanized antibodies that bind to EphB4

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL9001052A (nl) * 1990-05-02 1991-12-02 Tno Werkwijze voor het bepalen van een specifiek ligand in een vloeibaar monster met behulp van een evanescent veld, alsook een daarvoor geschikt onderdeel van de benodigde meetinrichting.
AU8931291A (en) * 1990-10-16 1992-05-20 Regents Of The University Of Michigan, The Cytokine-induced marker for inflammatory response

Also Published As

Publication number Publication date
ATE172246T1 (de) 1998-10-15
NO951861D0 (no) 1995-05-11
AU5599794A (en) 1994-06-08
DE69321555T2 (de) 1999-06-24
EP0597503A2 (en) 1994-05-18
NO951861L (no) 1995-07-11
EP0597503A3 (en) 1995-05-24
DE69321555D1 (de) 1998-11-19
US5650504A (en) 1997-07-22
AU685765B2 (en) 1998-01-29
DK0597503T3 (da) 1999-06-23
ES2121915T3 (es) 1998-12-16
JPH08505765A (ja) 1996-06-25
EP0597503B1 (en) 1998-10-14
CA2149333C (en) 2002-01-22
CN1094446A (zh) 1994-11-02
US5716934A (en) 1998-02-10
WO1994011020A1 (en) 1994-05-26
FI952328A (fi) 1995-07-10
IL107599A0 (en) 1994-02-27
CA2149333A1 (en) 1994-05-26

Similar Documents

Publication Publication Date Title
FI952328A0 (fi) eck-respetorin lignandeja
WO1996036713A3 (en) Eck receptor ligands
Smith et al. The active form of tumor necrosis factor is a trimer.
DE68907407D1 (de) Verfahren zur sequenzanalyse von dna.
ATE87655T1 (de) Markierer der t-zelle aktivierung.
NO903059L (no) Ligander og reseptorer omfattende nevnte ligander, fremgangsmaate for deres fremstilling og anvendelse.
ES2174855T3 (es) Metodos diagnosticos y composiciones farmaceuticas que se basan en proteinas notch y acidos nucleicos.
ATE380038T1 (de) Radiometall-bindende peptide analoge
DE3587888D1 (de) Mittel zum Abtrennen von Proteinen aus Blutplasma.
DK165199C (da) Aktivatorpraeparat, fremgangsmaade til kvantitativ bestemmelse af protein c under anvendelse af praeparatet, antithrombotisk laegemiddel indeholdende praeparatet og fremgangsmaade til udvinding af aktiveret protein c under anvendelse af praeparatet
DE68921185D1 (de) Verfahren und Zusammensetzungen zum Pelletisieren von Partikeln.
WO1994023030A3 (en) Methods and materials relating to the functional domains of dna binding proteins
AU698862B2 (en) A screening method for identifying ligands for target proteins
Conrad et al. Characterization of the target cell receptor for IgE—I. Solubilization of IgE-receptor complexes from rat mast cells and rat basophilic leukemia cells
PT84089A (en) Dna sequences coding for proteins having the biological activity of husi-type i inhibitors biotechnological methods for the preparation of said proteins and pharmaceutical compositions containing said proteins
DK71986A (da) Polypeptider fra rhinovirusstamme hrv2 samt de herfor kodende dna-molekyler, fremgangsmaade til polypeptidernes fremstilling og deres anvendelse
DE58907880D1 (de) Verfahren zur Herstellung aminierter Diketodi(het)aryl-pyrrolopyrrole und Verwendung derselben als photoleitfähige Substanzen.
DE59508137D1 (de) Spezifische bindungssubstanzen für antikörper und deren verwendung für immunoassays oder vakzine
ATE48142T1 (de) Blutprotein, verfahren zu seiner herstellung, antikoerper gegen dieses protein und dieses protein oder diese antikoerper enthaltende pharmazeutische zubereitungen.
ATE432349T1 (de) Modifizierte hämoglobinähnliche verbindungen und verfahren zu deren reinigung
DE3790139D2 (en) Antiparatypical antibodies, their use for detecting and treating auto-immune diseases
DE3889232D1 (de) Verfahren zum quantitativen Nachweis von Sauerstoff.
DE3688451D1 (de) Konjugate von vinblastin und seine derivate, verfahren zur herstellung derselben und diese konjugate enthaltende pharmazeutische zusammensetzungen.
DE69836226D1 (de) Ifn rezeptor 1 bindende proteine, dafür kodierende dna und verfahren zur regulierung der zellulären antwort auf interferone
ATE91156T1 (de) Verfahren zur sequenzanalyse von dna.

Legal Events

Date Code Title Description
FD Application lapsed